A Phase 1/2, Open-Label, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Metastatic, Androgen-Independent Prostate Cancer Subjects
收藏DataCite Commons2024-12-02 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00009349/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of this study is to determine the safety and tolerability of TAK-700 in patients
with asymptomatic metastatic, androgen independent prostate cancer.
提供机构：
Vivli
创建时间：
2023-10-06
